MIT engineers have developed synthetic nanoparticles that can be injected into the body to enhance blood clotting at sites of internal injuries, potentially saving lives during emergencies before hospital treatment. This two-component system mimics the body’s natural clotting process more effectively than previous hemostatic nanoparticles. In testing with a mouse model, the new system demonstrated remarkable efficiency in promoting recovery from severe injuries. The technology includes a nanoparticle that attracts platelets to injury sites and a polymer that mimics fibrinogen, essential for clot formation. This innovation allows for selective gelation at the wound site by increasing component concentration, replicating the natural clotting cascade.
With traumatic blood loss from incidents like car accidents resulting in over 2.5 million deaths annually worldwide, rapid intervention is crucial. The researchers found that their artificial clots are more durable than natural ones and do not trigger significant immune reactions. Plans for future studies include testing the system in larger animals and integrating portable imaging devices to locate bleeding sites, reducing delays in emergency treatment. The research is supported by the U.S. Army Research Office and the Department of Defense, showcasing its significance in military and civilian healthcare.
